Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wyeth |
---|---|
Information provided by: | Wyeth |
ClinicalTrials.gov Identifier: | NCT00581451 |
Safety and Tolerability study in healthy volunteers
Condition | Intervention | Phase |
---|---|---|
Healthy |
Drug: bifeprunox |
Phase I |
Study Type: | Interventional |
Study Design: | Randomized, Double Blind (Subject, Caregiver, Investigator), Single Group Assignment, Safety Study |
Official Title: | A 3-Part, Randomized, Multiple-Dose, Sequential Design Study of Bifeprunox in Healthy Subjects in Order to Establish a Titration Regimen With an Improved Tolerability Profile |
Estimated Enrollment: | 144 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
A: Experimental
bifeprunox 25 day
|
Drug: bifeprunox
oral tablet once daily
|
B: Experimental
bifeprunox 14 day
|
Drug: bifeprunox
oral tablet once daily
|
C: Experimental
bifeprunox 14 day
|
Drug: bifeprunox
oral tablet once daily
|
D: Experimental
bifeprunox 9 day
|
Drug: bifeprunox
oral tablet once daily
|
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Responsible Party: | Wyeth ( Wyeth (Registry Contact: Clinical Trial Registry Specialist) ) |
Study ID Numbers: | 3168A2-1005 |
Study First Received: | December 21, 2007 |
Last Updated: | December 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00581451 |
Health Authority: | United States: Food and Drug Administration |
inpatient ascending dose study to evaluate safety and tolerabi |
Healthy |